Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | October 30, 2025 | November 03, 2025 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP & President, Research | May 03, 2023 | May 04, 2023 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | Director | February 26, 2026 | March 02, 2026 |
| Juno Therapeutics, Inc.JUNO · Entity 168572 | Director | April 13, 2017 | April 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date October 30, 2025 · Filed November 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,987 |
Reported balance
After 2025-10-30 transaction · row 1
1 source rowRow 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 10,987 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
After 2025-10-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.32 · Expires 2029-06-30 | Direct | 2,352 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,352 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 3,511 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
BRISTOL MYERS SQUIBB CO
Report date May 03, 2023 · Filed May 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 47,751 |
Reported balance
After 2023-05-03 transaction · row 1
1 source rowRow 1 · 2023-05-03 · Sale · Disposed 50,385 · Balance 47,751 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBMS Savings and Investment Program | 655.73 |
Reported balance
Holding disclosure · report date 2023-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 655.73 F2: Based on recent 401(k) plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2: Based on recent 401(k) plan statement.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Juno Therapeutics, Inc.
Report date April 13, 2017 · Filed April 19, 2017
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-11-20 · Grant · Acquired 8,634 · Balance 22,812 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 13,906 · Balance 36,718 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 24,209 · Balance 60,927 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 60,927 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 613 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.57 · Expires 2025-02-02 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 19,142 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.90 · Expires 2025-05-04 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $132.56 · Expires 2025-07-27 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.08 · Expires 2025-11-09 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.80 · Expires 2026-02-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 2,344 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.97 · Expires 2026-05-02 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 9,680 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.69 · Expires 2026-08-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.18 · Expires 2026-10-31 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 31,210 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2019-11-20 · Disposition to issuer · Disposed 26,308 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-11-20 · Disposition to issuer · Disposed 5,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-11-20 · Disposition to issuer · Disposed 3,120 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-11-20 · Disposition to issuer · Disposed 9,271 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2019-11-20 · Disposition to issuer · Disposed 5,794 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2019-11-20 · Disposition to issuer · Disposed 37,660 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F3: This option was fully exercisable.
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2018 Filed May 8, 2018 16:36 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 781 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000697 · form4-05082018_010520.xml · derivative · entry 6 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:36 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,154 | $86.89 | $100,271.06 |
DisclosureSEC source: 0001415889-18-000697 · form4-05082018_010520.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537 Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:36 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000697 · form4-05082018_010520.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The performance stock units granted to the reporting person on May 4, 2015, vested and settled for shares of the Company's common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:36 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 384 | $86.89 | $33,365.76 |
DisclosureSEC source: 0001415889-18-000697 · form4-05082018_010520.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,347 Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:36 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 781 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000697 · form4-05082018_010520.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 16:39 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 5,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007525 · doc4.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The balance of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)). F1 · derivative.exercise_date: The balance of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The balance of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 16:39 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,673 | $99.80 | $266,765.40 |
DisclosureSEC source: 0001209191-18-007525 · doc4.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,950 Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 16:39 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 5,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007525 · doc4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The balance of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:42 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 11,384 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001209191-18-006234 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 Underlying: Common Stock · 11,384 shares Expires 2028-01-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 29, 2019. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 3,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-058433 · doc4.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120 Underlying: Common Stock · 3,120 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 26,308 | Not disclosed Strike: $100.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-058433 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,308 Underlying: Common Stock · 26,308 shares Expires 2027-10-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:54 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 11,384 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001209191-17-046932 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 Underlying: Common Stock · 11,384 shares Expires 2027-07-31 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 781 | Not disclosed Strike: $100.80 | Not disclosed |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 781 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly the 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 3,226 | Not disclosed Strike: $104.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · derivative · entry 6 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 Underlying: Common Stock · 3,226 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly the 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 778 | $120.15 | $93,476.70 |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $120.14 to $120.15, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 4,007 | $120.18 | $481,561.26 |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 781 | $100.80 | $78,724.80 |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,226 | $104.97 | $338,633.22 |
DisclosureSEC source: 0001209191-17-040468 · doc4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:21 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 5,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029194 · doc4.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,756 Underlying: Common Stock · 5,756 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:21 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 11,384 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001209191-17-029194 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 Underlying: Common Stock · 11,384 shares Expires 2027-05-01 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 4,000 | $124.42 | $497,672.00 |
DisclosureSEC source: 0001209191-17-016507 · doc4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778 Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 5,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008045 · doc4.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,623 Underlying: Common Stock · 5,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_price: The balance of the restricted stock units will vest on February 2, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,995 | $115.54 | $230,502.30 |
DisclosureSEC source: 0001209191-17-008045 · doc4.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,778 Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 5,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008045 · doc4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on February 2, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:26 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 12,906 | Not disclosed Strike: $113.18 | Not disclosed |
DisclosureSEC source: 0001209191-17-006374 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,906 Underlying: Common Stock · 12,906 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document |
| November 22, 2016 Filed Nov 30, 2016 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 2,500 | $123.18 | $307,950.00 |
DisclosureSEC source: 0001209191-16-152461 · doc4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:16 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147905 · doc4.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:16 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 31,210 | $0.00 Strike: $102.18 | $0.00 |
DisclosureSEC source: 0001209191-16-147905 · doc4.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,210 Underlying: Common Stock · 31,210 shares Expires 2026-10-31 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.